Date: December 2, 2021
Time: 8:00am (PDT), 11:00am (EDT)
Effective immunotherapy of pancreatic ductal adenocarcinoma (PDAC) is hampered by the lack of suitable tumor-specific antigens. To address this challenge, we have combined high-throughput flow cytometry with high-content cyclic immunofluorescence for the early identification of target candidates for cellular immunotherapy. Within this webinar, we aim to guide the viewers through our most recently published scientific findings and related cutting-edge tools, ranging from the preparation of primary and xenografted tumor specimens to the comprehensive antigen screening and deep phenotyping.  Schäfer, D., Tomiuk, S., Küster, L.N. et al. Identification of CD318, TSPAN8 and CD66c as target candidates for CAR T cell based immunotherapy of pancreatic adenocarcinoma. Nat Commun 12, 1453 (2021).
- Identify the problem of solid tumor CAR T cell therapies in that most identified tumor-associated antigens are also expressed in healthy tissue.
- Discuss high-throughput flow cytometry followed by high-content immunofluorescent imaging are ideal tools for systematically screening for CAR targets.
- Discuss how CD318, TSPAN8 and CD66c were identified as potential targets for CAR T cell based immunotherapy of PDAC.
Webinars will be available for unlimited on-demand viewing after live event.
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.